Why the study?
While plasma stability for bivalirudin had been reported, its stability in whole blood at room temperature remained unknown.
Bivalirudin is stable in citrated plasma for 24 hours at room temperature, but whole blood samples should be processed within 6 hours to avoid clinically significant deterioration.
Answers are grounded in this paper and cite their sources.
ROTEM may aid point-of-care bivalirudin monitoring in ECMO/VAD; leaves open validation against plasma assays before adoption.
Bivalirudin is a direct thrombin inhibitor widely used in many hospitals in the setting of heparin failure or as a primary anticoagulant in patients on extracorporeal membrane oxygenation (ECMO) or a ventricular assist device. For monitoring bivalirudin, activated partial thromboplastin time (aPTT), aPTT with heparinase, 1:10 dilute thrombin time (dTT), ecarin chromogenic assay, or ecarin clotting time testing is performed using citrated plasma samples.1 Thromboelastometry (ROTEM) using citrated whole blood is also used to monitor global hemostasis in ECMO patients anticoagulated with bivalirudin.2 Approximately 80% of bivalirudin is metabolized as proteolysis in vivo. Although plasma stability for bivalirudin was recently reported,3 the stability of this anticoagulant in whole blood is unknown. There are a few possible clinical scenarios that can occur when samples are not processed to plasma right away: if a whole blood specimen is sent from a satellite hospital or it is sent for ROTEM or thromboelastography and bivalirudin level assay can be an add-on later. The purpose of this study was to determine bivalirudin stability in citrated specimens at room temperature.Citrated whole blood of individual donors was pooled in 8-mL aliquots and spiked with 80 µL of 62.5 and 125 µg/mL bivalirudin (Angiomax, Maia Pharms Inc, Princeton, New Jersey) to obtain approximate final plasma concentrations of bivalirudin of 1.0 and 2.0 µg/mL. Two-milliliter aliquots of spiked whole blood were centrifuged to obtain citrated plasma and removed from cells. A 1:10 dTT was then measured at predetermined time points. One-milliliter aliquots of whole blood were collected at similar time points, spun, and 1:10 dTTs were measured. Experiments were repeated in 4 donors (2 females), with data presented as mean ± SD.The 1:10 dTT was performed on STA MAX analyzer (Diagnostica Stago, Parsippany, New Jersey) using 10 μL of patient plasma mixed with 90 μL of normal pooled plasma (Precision BioLogic), then 100 μL of thrombin time reagent.4 Bivalirudin concentrations were determined based on calibration curve prepared by spiking bivalirudin into normal pooled plasma at levels of 0.5 to 3.0 µg/mL. Initial bivalirudin measured values were close to calculated (Table) and remained similar up to 24 hours at room temperature in the citrated plasma that was removed from the cells. Bivalirudin levels in whole blood showed approximately 20% deterioration at 24 hours, but they remained stable in whole blood up to 6 hours. The target range of bivalirudin level can be narrow and low, such as 0.8 to 1.2 μg/mL, when the patient has bleeding symptoms. In that case, a 20% lower level can be clinically significant.We confirmed that bivalirudin is stable for 24 hours in plasma; however, the drug stability in whole blood is “at least” 6 hours, and additional studies are required to determine at what time point beyond 6 hours the recovery drops off in a clinically significant way.
No takes yet. Share an insight, caveat, or question.
Bruzdoski et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: